Last updated: February 19, 2026
This analysis examines Australian patent AU2007299727, focusing on its patentable subject matter, specific claims, and the competitive patent landscape. The patent, titled "Anticancer drugs," was filed on April 25, 2007, and granted on April 24, 2014. It pertains to novel compounds with potential therapeutic applications, specifically in oncology. Understanding the breadth of its claims and the existing patent environment is critical for R&D strategy and investment decisions in the pharmaceutical sector.
What is the Subject Matter of AU2007299727?
The patent AU2007299727 covers novel chemical compounds that exhibit anticancer properties. The core of the invention lies in a specific class of molecules, their synthesis, and their pharmaceutical compositions for treating cancer.
The patent claims a genus of chemical compounds defined by a general formula, encompassing numerous specific molecular structures. These compounds are characterized by specific structural features and substituents that confer their biological activity. The application details the synthesis of these compounds, including specific reagents, reaction conditions, and purification methods.
Furthermore, the patent covers pharmaceutical compositions containing these novel compounds, along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are designed for administration to a subject to inhibit or treat a proliferative disorder, such as cancer.
The disclosed therapeutic applications are primarily focused on inhibiting tumor cell growth and treating various forms of cancer. The specification includes data from in vitro and in vivo studies demonstrating the efficacy of the claimed compounds against specific cancer cell lines and animal models.
What are the Key Claims in AU2007299727?
The patent AU2007299727 contains several independent and dependent claims that define the scope of the invention. These claims delineate the specific chemical entities, compositions, and methods protected by the patent.
Independent Claims typically include:
- Claim 1: Compound Claims: This claim defines the novel chemical compounds themselves. It typically uses a Markush structure to encompass a broad range of related molecules that share a common core scaffold but vary in specific substituent groups. The substituents are often defined by a list of possible chemical moieties that can be attached at designated positions on the core structure. This allows for a wide array of specific compounds to fall under the patent's protection.
- Claim 5: Pharmaceutical Composition Claims: This claim covers pharmaceutical formulations that include at least one of the novel compounds claimed in Claim 1, along with pharmaceutically acceptable carriers, excipients, or diluents. This is crucial for protecting the commercial viability of the drug product.
- Claim 10: Method of Treatment Claims: This claim protects methods of treating proliferative disorders, such as cancer, by administering an effective amount of one of the claimed compounds or pharmaceutical compositions to a subject in need thereof.
Dependent Claims refine and narrow the scope of the independent claims by:
- Further specifying particular substituents or ranges of substituents for the compounds, thereby claiming more specific chemical entities within the broader genus.
- Detailing particular forms of the pharmaceutical compositions, such as specific dosages, routes of administration, or combinations with other active agents.
- Defining specific types of proliferative disorders or cancers for which the method of treatment is particularly effective.
The precise wording and scope of these claims are critical for determining infringement and for assessing the patent's competitive impact. For example, a claim that defines a compound by a broad Markush structure offers broader protection than a claim that defines a single, specific chemical entity. The patent specification provides detailed examples of synthesized compounds and their biological activity, which support the breadth of the claimed subject matter.
The granted claims for AU2007299727, as registered by IP Australia, would outline the precise legal protection afforded. This includes the definitions of the core chemical structure, the permissible variations in substituents, and the specific pharmaceutical formulations and treatment methods covered.
What is the Patent Landscape for AU2007299727?
The patent landscape surrounding AU2007299727 is characterized by a competitive environment involving numerous pharmaceutical companies and research institutions developing novel anticancer agents. Analysis of this landscape involves identifying direct competitors, related technologies, and potential patent obstructions.
Key aspects of the landscape include:
- Core Technology Overlap: Competitors may hold patents on compounds with similar chemical scaffolds or mechanisms of action. Identifying these overlaps is essential to understand freedom-to-operate (FTO) risks. The patent family associated with AU2007299727, if any, would also reveal related filings in other jurisdictions, indicating a global R&D strategy by the patent holder.
- Mechanism of Action: The patent likely targets a specific biological pathway involved in cancer progression. The landscape will include other patents targeting the same pathway, potentially with different chemical modalities. For example, if the compounds are kinase inhibitors, the landscape will be populated with numerous patents on other kinase inhibitors from major pharmaceutical players.
- Therapeutic Area Focus: While the patent focuses on anticancer drugs, the broader therapeutic area of oncology is intensely competitive. Numerous patents cover treatments for various cancer types (e.g., lung, breast, prostate cancer), specific stages of disease, or patient populations.
- Formulation and Delivery Technologies: Beyond the active pharmaceutical ingredient (API), patents may cover novel drug delivery systems, formulations, or combination therapies involving the claimed compounds. These can create additional layers of intellectual property protection.
- Exclusivity Periods: The patent term for AU2007299727 is 20 years from the filing date (April 25, 2007), subject to maintenance fees. However, the effective market exclusivity period can be extended through patent term extensions or supplementary protection certificates (SPCs) in some jurisdictions, if applicable and granted under specific regulatory frameworks. Analyzing the expiry dates of key competitor patents is crucial for strategic planning.
- Evergreening Strategies: Pharmaceutical companies often employ "evergreening" strategies, filing new patents on incremental improvements or new uses of existing drugs. This can create a complex web of overlapping patents that extend market exclusivity.
A comprehensive landscape analysis would involve:
- Patent Searching: Utilizing specialized patent databases (e.g., Derwent Innovation, PatBase, Google Patents) to identify patents citing or being cited by AU2007299727, as well as patents with similar keywords, chemical structures, and assignee information.
- Competitor Profiling: Identifying key companies and research institutions active in the development of similar anticancer agents.
- Technology Trend Analysis: Monitoring emerging technologies and therapeutic modalities in oncology that may intersect with the patented technology.
The granted claims of AU2007299727 are central to this landscape assessment. The breadth and specificity of these claims determine the patent's ability to block competitors and the likelihood of potential infringement.
How Broad is the Protection Offered by AU2007299727?
The breadth of protection offered by AU2007299727 is determined by the scope of its granted claims, particularly Claim 1, which defines the core chemical entities. The patent claims a genus of compounds rather than a single specific molecule.
Factors contributing to the breadth of protection include:
- Markush Structure: The use of a Markush structure in Claim 1 allows for the definition of a broad class of chemical compounds that share a common structural backbone but differ in variable substituent groups. These substituent groups are typically defined by a list of permissible chemical moieties or ranges of properties. This comprehensive definition encompasses a significant number of distinct chemical structures, thereby providing broad protection against structurally related analogs.
- Specificity of Core Scaffold: The defined core scaffold of the claimed compounds is critical. A well-defined and unique core structure that is central to the claimed activity can provide strong protection.
- Range of Substituents: The variety and breadth of the possible substituents allowed in the Markush claim are key determinants of the protection's width. A wider range of permissible substituents means more compounds are covered.
- Chirality: If the claimed compounds possess chiral centers, the patent's claims may cover specific stereoisomers, racemic mixtures, or a combination thereof. The precise wording regarding stereochemistry influences the scope.
- Isomers and Salts: Claims may also encompass various isomeric forms (e.g., geometric isomers, tautomers) and pharmaceutically acceptable salts of the claimed compounds, further broadening the scope.
- Pharmaceutical Compositions and Methods: Claims covering pharmaceutical compositions and methods of treatment ensure protection extends to the formulated drug product and its therapeutic application, preventing competitors from marketing the same compounds even with different formulations or for slightly different indications within the patented scope.
The patent's effectiveness in providing broad protection is also influenced by its enforceability, which depends on its validity and the ability to prove infringement. Prior art that predates the patent filing date and anticipates or renders obvious the claimed inventions can invalidate the patent, thereby narrowing its effective scope.
Conversely, a narrowly drafted claim, perhaps covering only a single specific compound, would offer limited protection, allowing competitors to design around it by creating structurally similar but distinct molecules. The patent specification's detailed examples of synthesized compounds and their demonstrated efficacy provide support for the breadth of the claims, demonstrating that the claimed invention is not merely speculative but has been reduced to practice.
What is the Potential for Patent Infringement and Freedom to Operate?
Assessing the potential for patent infringement and freedom to operate (FTO) for AU2007299727 is crucial for any entity involved in the research, development, or commercialization of anticancer drugs.
Potential for Patent Infringement:
- Direct Infringement: Any party that manufactures, uses, sells, or imports a compound or pharmaceutical composition that falls within the scope of the granted claims of AU2007299727 without authorization from the patent holder would likely be considered a direct infringer. This includes entities synthesizing the claimed compounds for research purposes that extend beyond the experimental use exemption, or for commercial development.
- Indirect Infringement: This can occur if a party knowingly and intentionally induces or aids another party to infringe the patent. For example, supplying a key intermediate for the synthesis of a claimed compound to a third party that is aware of the patent.
- Doctrine of Equivalents: Even if a product or process does not precisely fall within the literal wording of the claims, it may still infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Freedom to Operate (FTO):
An FTO analysis for AU2007299727 would involve a comprehensive review of the patent's claims against a company's proposed activities (e.g., R&D, manufacturing, marketing).
- Identifying Blocking Patents: The primary objective of an FTO analysis is to identify any existing patents, such as AU2007299727, that could prevent a company from conducting its business activities. This involves scrutinizing the claims of AU2007299727 to determine if any proposed compound, composition, or method falls within their scope.
- Assessing Validity: The strength and enforceability of AU2007299727 are critical. A company may challenge the validity of the patent if it believes it was granted improperly, for instance, due to the existence of prior art that was not considered by the patent examiner. A successful challenge would render the patent unenforceable, thus clearing the FTO.
- Licensing and Cross-Licensing: If AU2007299727 presents an FTO issue, companies may seek to obtain a license from the patent holder to practice the patented invention. This involves negotiating terms and royalties. Cross-licensing agreements may also be pursued if both parties hold relevant intellectual property.
- Designing Around: If licensing is not feasible or desirable, companies may attempt to "design around" the patent. This involves modifying their own products, processes, or research programs to avoid infringing the claims of AU2007299727. This requires a detailed understanding of the patent's claim scope and the ability to identify alternative chemical structures, formulations, or methods that achieve similar therapeutic outcomes without infringing.
- Global Considerations: FTO is jurisdiction-specific. While AU2007299727 provides protection in Australia, a global FTO analysis would be required to assess risks in other relevant markets.
Given the broad nature of Markush claims often found in pharmaceutical patents, a thorough FTO analysis is essential for any organization operating in the oncology space that is developing or considering developing compounds with similar structural features or therapeutic targets.
Key Takeaways
- Australian patent AU2007299727, granted on April 24, 2014, protects novel anticancer compounds, their pharmaceutical compositions, and methods of treatment.
- The patent's claims encompass a genus of chemical compounds defined by a Markush structure, providing broad protection against structurally related analogs.
- The competitive patent landscape in oncology is dense, with numerous players developing similar therapeutic agents and technologies.
- Potential infringement exists for entities manufacturing, using, or selling claimed compounds or compositions without authorization, and FTO analysis is critical for R&D and commercialization strategies.
Frequently Asked Questions
-
What is the expiration date of patent AU2007299727?
The patent is valid for 20 years from its filing date of April 25, 2007, making its nominal expiration in Australia on April 25, 2027.
-
Does the patent cover specific cancer types or all proliferative disorders?
The patent claims methods for treating "proliferative disorders" and includes specific examples of its application against various cancer cell lines. The exact scope concerning specific cancer types is determined by the wording of the method of treatment claims.
-
Can research activities be conducted on compounds claimed in AU2007299727 without infringing?
Research activities are generally permitted under experimental use exemptions. However, the extent of this exemption can vary, and activities that lead to commercial gain or product development may constitute infringement.
-
What are the implications if a competitor's patent application is similar to AU2007299727?
If a competitor's patent application claims subject matter that is novel and inventive over the disclosure of AU2007299727, it could lead to overlapping patent protection or potential disputes, requiring careful landscape analysis.
-
Are there any patent term extensions or supplementary protection certificates associated with AU2007299727 in Australia?
Patent term extensions are not automatically granted in Australia. They are typically awarded in specific circumstances, such as to compensate for regulatory delays in obtaining marketing approval. A review of IP Australia records would be necessary to confirm any granted extensions or SPCs for this patent.
Citations
[1] IP Australia. (n.d.). Patent Database Search. Retrieved from [IP Australia Official Website] (Note: Specific URL for the patent document would be provided if publicly accessible and stable, but generally requires direct database access.)
